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Aims Neuropilins 1 and 2 (NRP1 and NRP2) play crucial roles in endothelial cell migration contributing to angiogenesis and
vascular development. Both NRPs are also expressed by cultured vascular smooth muscle cells (VSMCs) and are
implicated in VSMCmigration stimulated by PDGF-BB, but it is unknownwhether NRPs are relevant for VSMC function
in vivo. We investigated the role of NRPs in the rat carotid balloon injury model, in which endothelial denudation and
arterial stretch induce neointimal hyperplasia involving VSMC migration and proliferation.
Methods
and results
NRP1 and NRP2 mRNAs and proteins increased significantly following arterial injury, and immunofluorescent staining
revealed neointimal NRP expression. Down-regulation of NRP1 and NRP2 using shRNA significantly reduced neointi-
mal hyperplasia following injury. Furthermore, inhibition of NRP1 by adenovirally overexpressing a loss-of-function
NRP1 mutant lacking the cytoplasmic domain (DC) reduced neointimal hyperplasia, whereas wild-type (WT) NRP1
had no effect. NRP-targeted shRNAs impaired, while overexpression of NRP1 WT and NRP1 DC enhanced, arterial
re-endothelialization 14 days after injury. Knockdown of either NRP1 or NRP2 inhibited PDGF-BB-induced rat VSMC
migration, whereas knockdown of NRP2, but not NRP1, reduced proliferation of cultured rat VSMC and neointimal
VSMC in vivo. NRP knockdown also reduced the phosphorylation of PDGFa and PDGFb receptors in rat VSMC, which
mediate VSMC migration and proliferation.
Conclusion NRP1 and NRP2 play important roles in the regulation of neointimal hyperplasia in vivo by modulating VSMC migration
(via NRP1 and NRP2) and proliferation (via NRP2), independently of the role of NRPs in re-endothelialization.
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1. Introduction
Percutaneous transluminal coronary angioplasty (PTCA) continues to
be used for coronary revascularization for emergency heart attack
and for angina refractory to standard medical therapy, with 2 million
procedures worldwide every year (www.ptca.org). The principal rea-
son for failure of PTCA is restenosis, particularly in diabetics. A major
underlying cause of restenosis, as well as of stenosis following coronary
bypass and other vascular grafting, is the abnormal accumulation of
neointimal vascular smooth muscle cells (VSMCs) resulting from
media-to-intima migration and proliferation. These processes, together
with deposition of extracellular matrix, lead to neointimal hyperplasia,
causing luminal narrowing, thereby limiting the beneficial effects of
intervention. The development of drug-eluting stents has considerably
improved the outcome and is now the preferred method of revascular-
ization, but restenosis remains an important cause for the failure of
revascularization therapy.
Neuropilin 1 (NRP1) is a receptor for Class 3 semaphorins which
regulate axonal guidance and neuronal patterning during embryogen-
esis,1,2 and for members of the VEGF family of angiogenic cytokines
in endothelial cells, with an essential role in vascular development.3,4
NRPs are also increasingly recognized to be important mediators of
other physiological and pathophysiological processes, including immu-
noregulation and tumourigenesis.5 NRP1 and the related molecule,
NRP2, share a similar domain structure with a large multi-domain
extracellular region essential for ligand binding, a single transmembrane
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domain and a small intracellular domain.5 NRP1 complexes with VEGF
receptor 2 (VEGFR2) in the endothelium and mediates VEGF signalling
important for directed cell migration, a function at least partly depend-
ent on the NRP1 cytoplasmic domain.6–9 Furthermore, NRP1 is also
able to mediate the cellular functions of non-canonical NRP1 ligands
involving signalling and complexation with other growth factor recep-
tors, including PDGF/PDGF receptors(R), fibroblast growth factor-2
(FGF-2),10 and transforming growth factor b (TGF-b) and its recep-
tors.11 –16 NRPs are highly expressed in VSMCs, mesenchymal stem
cells (MSC), and hepatic stellate cells and mediate migration of these
cells in response to PDGF by associating with PDGFRa and b, thereby
regulating their phosphorylation state and downstream chemotactic
signalling.11,13,15,17 It is so far unclear whether NRP1 plays a role in
VSMC function in vivo. PDGF signalling is known to be a key regulator
of VSMC migration following endovascular injury;18 PDGF-BB and its
receptors, PDGFRa and PDGFRb, are differentially up-regulated in a
time-dependent manner after angioplasty.19 Other growth factors,
such as FGF-2, are also strongly implicated in migration and proliferation
of VSMC leading to neointima formation induced by endovascular in-
jury.20We examinedwhetherNRPs play a role in neointimal remodelling
induced by balloon angioplasty in the rat carotid artery, a well-
characterized model of arterial remodelling following endothelial
denudation. We found that endogenous NRP1 and NRP2 were up-
regulated following arterial injury, and that disruption of NRP function
either by overexpressing a NRP1 mutant lacking the cytoplasmic domain
(NRP1 DC) or by targeted knockdown of NRP1 and NRP2, significantly
reduced neointimal hyperplasia following arterial injury. Interestingly,
NRP2 knockdown also selectively reduced neointimal VSMC prolifer-
ation and decreased the migration and proliferation of cultured VSMC,
whereas NRP1 knockdown inhibited only VSMC migration. NRP1 and
NRP2 inhibition also impaired re-endothelialization and reduced endo-
thelial cell migration. These findings indicate novel roles for NRPs in
mediating pathological VSMC accumulation, neointimal thickening, and
endothelial regeneration in response to endovascular injury.
2. Materials and methods
An expanded Methods section is available in the Supplementary mater-
ial online.
2.1 Rat carotid injury model, adenovirus
treatments, and morphometry
All animal experiments were performed in compliance with the Ani-
mals (Scientific Procedures) Act (1986) and in accordance with
Home Office and University College London guidelines. Animals
were anaesthetized using a combination of Midazolam (625 mg/
100 g) and Fentanyl (40 mg/100 g) supported by Halothan 0.5% at
2 L/min oxygen flow. Carotid injury in anaesthetized male Sprague-
Dawley rats (Charles River UK) was performed using an embolectomy
catheter as previously described (see Supplementary material on-
line).21 Adenoviruses (Ad) were delivered to injured carotid arteries
in pluronicw gel F-127 (Sigma-Aldrich) containing 1010 adenoviral par-
ticles applied to the adventitial surface of the artery. Specimen retrieval
was done following perfusion under terminal anaesthesia using pento-
barbital via intraperitoneal injection. Two hundredmillilitres of 0.9% sa-
line solution was perfused at a rate of 20 mL/min via the abdominal
aorta. The specimens were then carefully dissected through neck inci-
sion. Neointimal hyperplasia was assessed by determining the ratios of
the intimal to medial areas (I/M) in haematoxylin- and eosin-stained
paraffin-embedded sections using ImageJ.22,23 Re-endothelialization
was assessed by immunohistochemical staining of endothelial nitric
oxide synthase (eNOS)24 – 26 and also using Evan’s blue staining of
the whole artery.
2.2 Expression studies, cell culture,
adenoviruses, and cell migration
Measurement of gene expression by absolute quantitative RT-PCR
(qPCR) (see Supplementary material online, Table S1 for primers),
western blotting, immunofluorescent and immunohistochemical staining,
generation of adenoviruses encoding NRP1 constructs and shRNAs tar-
geted to NRP1 and NRP2, culture of rat aortic SMC (RAoSMC) and rat
aortic endothelial cells (RAoEC), and assays of cell migration was per-
formed as previously described11,21–23,27–29 (see expanded Methods
section in the Supplementary material online).
2.3 Cell proliferation
Carotid artery neointimal proliferation was determined by bromodeox-
yuridine (BrdU) labelling. BrdU solution (Sigma-Aldrich) was injected in
rats intraperitoneally 24 h prior to tissue harvest. BrdU-labelled cells
were detected by immunostaining paraffin-embedded arterial sections
using anti-BrdU antibody (Dako, Glostrup, Germany). Proliferation of
cultured RAoEC was determined in 96-well plates (seeding density of
7000 cells per well) by assessing cell confluence in living cells using an
IncuCyteTM Zoom (Essen Bioscience) for up to 3 days.
2.4 Statistical analysis
Results are presented as means+ SEM. Statistical analysis was per-
formed using GraphPad Prism Version 5 by using either one-way or
two-way ANOVA with Bonferroni post tests, comparing a treatment
with control conditions. Repeated-measures two-way ANOVA was
made for cell proliferation assays and cell migration scratch assays per-
formed using the IncuCyteTM Zoom (Essen Bioscience). The number of
experiments or animals used in each study is specified for each figure.
Statistical significance was validated at *P, 0.05.
3. Results
3.1 Neuropilins are up-regulated following
angioplasty
Assessment of NRP1 gene regulation during the development of neoin-
timal hyperplasia by qPCR at 7, 14, and 28 days after injury of the left
carotid artery (LCA) showed that NRP1 mRNA copy number was sig-
nificantly increased at all time points in injured arteries compared with
the uninjured right carotid arteries (RCA). NRP2 mRNA expression
was also significantly elevated 7 days after angioplasty thereafter declin-
ing to control levels by 28 days after injury (Figure 1A). Assessment of
VEGFR2 (Flk1) mRNA showed a nearly two-fold increase in the gene
copy number 14 and 28 days after injury, but the mRNA copy number
was very low relative to that of NRPs, and VEGFR2 up-regulation was
not statistically significant (see Supplementary material online, Figure
S1). VEGFR2 up-regulation probably reflects endothelial cell prolifer-
ation and repopulation of the lumen after injury. NRP1 and NRP2 pro-
tein expression increased significantly after injury with a maximum
up-regulation at 7 and 14 days (Figure 1B). IF staining of arterial sections
revealed expression of NRP1 and NRP2 after arterial injury in the med-
ial and neointimal layers of the carotid 14 days after angioplasty
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(Figure 2A and B). Immunofluorescent staining of NRP1 and NRP2
showed extensive neointimal staining suggestive that NRP1 and
NRP2 were at least partly localized to VSMC (Figure 2C). Immunostain-
ing of VSMC with antibody to smooth muscle-specific a-actin (SMA)
also showed extensive neointimal staining, though for technical reasons
we were unable to quantify the extent of co-staining with NRPs. Some
luminal cells were positive for NRP1 and NRP2 immunostaining, and
these luminal cells showed co-staining for endothelial-specific eNOS
(Figure 2C). It was further noted that sparse cells within the neointima
were positive for both NRP1 and the monocyte/macrophage marker,
CD68, as well as for NRP2 and CD68, indicating that some neointimal
NRP positive cells were macrophages (Figure 2C). For NRP1, 5.9 and
2.7% immunofluorescent staining co-localized with eNOS and CD68,
respectively, and corresponding values for NRP2 were 12.9 and 2.2%.
3.2 Neuropilins play a role in neointimal
thickening induced by injury
The up-regulation of NRP1 and NRP2 in the carotid artery following in-
jury suggested a possible role of NRPs in increased VSMC migration
Figure 1 Neuropilins are up-regulated following carotid balloon angioplasty. Levels of NRP1 and NRP2 mRNA (A) and protein (B) expression were
determined in uninjured rat carotid arteries and at different times after left carotid arterial balloon injury by absolute qPCR andwestern blot, respectively.
Values for mRNA expression are means+ SEM; n ¼ 6 arteries, *P, 0.05, **P, 0.01, ***P, 0.001. Protein expression was quantified by scanning
densitometry of blots: means+ SEM; n ¼ 4, *P, 0.05, **P, 0.01.
C. Pellet-Many et al.290
contributing to neointimal thickening and arterial remodelling. To address
this possibility, we used two approaches: targeted knockdown ofNRP ex-
pression using small hairpin (sh) RNAs specific for NRP1 and NRP2 and
overexpression of adenoviral constructs encoding either a WT NRP1 or
a mutant NRP1 lacking the cytoplasmic domain (NRP1 DC) previously
shown to inhibit PDGF-BB-induced migration in human coronary artery
VSMC and VEGF-induced endothelial cell migration (see Supplementary
material online, Figure S2).6,11,13 Overexpression of Ad.shRNA constructs
targeted toNRPs in carotid arteries significantly and selectively decreased
NRP1 and NRP2 arterial mRNA and protein expression in vivo and pro-
tein expression in RAoSMC (see Supplementary material online, Figure
S3). Morphometric analysis of the transduced vessels revealed that over-
expression of either shNRP1 or shNRP2 significantly decreased neointi-
mal hyperplasia, evaluated by determining I/M, compared with the
shScrambled control at all time points (Figure 3A and C and see Supple-
mentary material online, Table S2). NRP2 knockdown reduced neointima
formation to a somewhat greater extent than NRP1 shRNA, though not
significantly so (P ¼ 0.1261). It was also examined whether combined
knockdown of NRP1 and NRP2 could inhibit neointima formation
more profoundly. The results of this experiment confirmed the inhibitory
effects of targeted knockdown of either NRP alone, with NRP2
knockdown again exerting a marginally greater effect, but showed that
the combined knockdown caused no greater inhibition than NRP2
shRNA alone (see Supplementary material online, Figure S4).
Delivery of Ad.NRP1WT and Ad.NRP1DCwas performed in pluro-
nic gel applied to the adventitial surface of carotid arteries at the time of
injury as described previously.30 The efficiency of arterial gene trans-
duction using this approach was demonstrated by examining expres-
sion of adenovirus-encoded Green Fluorescent Protein (Ad.GFP)
and LacZ (Ad.LacZ) by PCR and immunostaining 7 days after injury
and infection with vectors (see Supplementary material online, Figure
S5). Adenovirally delivered GFP and LacZ were strongly expressed in
injured rat carotid arteries, with substantial expression found in the
media, adventitia, and neointima, as indicated by PCR (GFP only)
(see Supplementary material online, Figure S5A) and immunohisto-
chemical staining (see Supplementary material online, Figure S5B). At
7 and 14 days post-injury, protein expression of adenovirally delivered
GFP or LacZ was detected, as indicated by western blot of whole ca-
rotid artery lysates, but expression decreased markedly at 28 days after
injury (see Supplementary material online, Figure S5C).
Morphometric analysis of the vessels revealed that overexpression
of the NRP1 DC mutant significantly decreased the formation of
Figure 2 Neointimal expression of NRPs after balloon injury. (A and B) Representative IF images of carotid arteries showing endogenous expression of
NRP1 (sc-7239, Santa Cruz) (A) and NRP2 (sc-13117, Santa Cruz) (B) following vascular injury in LCA (14 days after angioplasty) and in uninjured RCA
(n ¼ 3 for each treatment). Negative control staining with IgG and secondary antibody alone is shown in small photomicrographs at ×200 magnification.
(C) LCAwere harvested 28 days post-angioplasty and stained for either NRP1 (sc-7239, Santa Cruz), NRP2 (sc-54128, Santa Cruz), smoothmuscle cell a
actin (ab18460-1, Abcamw; SMA), CD68 (MCA341R, AbD Serotecw), or eNOS (610296, BD transduction laboratoriesTM) as an endothelial cell marker.
Co-staining of NRP1 and NRP2 with antibodies to eNOS and CD68 was performed on n ¼ 6 arteries. White arrows indicate selected areas of colo-
calization of NRPs with eNOS and CD68. Negative control staining with appropriate IgG control antibodies with DAPI counterstaining is shown. The
luminal side is placed as indicated on each panel, and the internal elastic lamina is visible by autofluorescence.
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neointimal hyperplasia compared with the Ad.LacZ and Ad.NRP1 WT
at 7 and 14 days post-injury (Figure 3B and D; see Supplementary mater-
ial online, Table S3). At 28 days after injury, I/M ratios were modestly
reduced compared with earlier times consistent with the observation
that intimal hyperplasia reaches a peak after 2–3 weeks following in-
jury and thereafter remains relatively constant.31 At this time point,
there was no statistically significant difference between arteries trans-
duced with LacZ, NRP1WT, and NRP1 DC adenoviruses. The lack of a
significant inhibitory effect of Ad.NRP1 DC at 28 days in part may re-
flect reduced adenoviral expression of this molecule at later times after
delivery as indicated by LacZ and GFP expression (see Supplementary
material online, Figure S5C).
3.3 Re-endothelialization and endothelial
function
Given that NRP1 has been shown to play an important role in endothe-
lial cell migration, we investigated whether reduced neointimal hyper-
plasia consequent upon NRP knockdown or overexpression of NRP1
DC could be due to an effect on re-endothelialization. Endothelial
luminal coverage was determined by immunostaining of eNOS at six
different levels across the whole length of the injured artery.
Continuous specific staining of the endothelium was observed in unin-
jured carotid arteries (see Supplementary material online, Figure S6A),
whereas staining was almost completely absent immediately after injury
(see Supplementary material online, Figure S6C) and progressively in-
creased thereafter to 75% luminal coverage 28 days following injury
(Figure 4A and B). Quantification of endothelial eNOS staining showed
that endothelial coverage was significantly reduced by Ad.shRNA tar-
geted to NRP1 at 14 days and by Ad.shRNA to NRP2 at 7 and 14 days,
but it was not significantly affected by Ad.shRNA at 28 days (Figure 4A).
In addition, en face staining of arteries using Evans blue dye at 14 days
after injury also revealed decreased re-endothelialization of vessels fol-
lowing knockdown of NRP1 and NRP2, though this effect was signifi-
cant only for Ad.shNRP1 vs. Ad.shScrambled (see Supplementary
material online, Figure S6G). The reduced re-endothelialization values
obtained from Evan’s blue staining compared with immunohistochem-
ical staining of eNOS may be due to leakage of dye in the
mitotic-regenerating endothelium.32 Overexpression of Ad.NRP1
WT or Ad.NRP1 DC had no significant effect on re-endothelialization
at 7 days, but at 14 days after injury, overexpression of both constructs
enhanced re-endothelialization compared with control Ad.LacZ-
transduced arteries (Figure 4B). Treatment with Ad.NRP1 WT also
caused a significant enhancement in re-endothelialization at 28 days
Figure 3 NRPs inhibition reduces neointima formation induced by balloon injury. Representative H&E pictures (A and B) andmorphometric analysis (C
andD) of left coronary arteries following arterial injury (7, 14, and 28 days post-injury) and delivery of adenoviruses encoding either shRNAs (A and C) or
Ad.LacZ, Ad.NRP1WT, and Ad.NRP1 DC (B and D). In A and B, dashed lines indicate the internal elastic lamina. In C and D, intima to media ratios were
determined by morphometric analysis using Image J: means+ SEM; n ¼ 6 animals per treatment at each time point, *P, 0.05.
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compared with Ad.LacZ (90 vs. 74%), while Ad.NRP1 DC had no sig-
nificant effect at this time. Given these results, we evaluated effects of
manipulating NRP expression on migration and proliferation in primary
cultures of RAoEC in response to VEGF. Overexpression of Ad.NRP1
WT significantly enhanced VEGF-induced RAoECmigration (from 32 h
onwards) and Ad.NRP1 DC significantly reduced RAoEC migration
(from 48 h onwards), while overexpression of NRP1 WT and NRP1
DC did not alter RAoEC proliferation (Figure 4D and F ). In contrast,
Ad.shRNAs targeted to either NRP1 or NRP2 significantly inhibited
RAoECmigration (from 28 and 32 h onwards for shNRP1 and shNRP2
Figure 4 NRP inhibition impairs re-endothelialization following endothelial denudation. (A and B) Re-endothelialization was determined by quantifi-
cation of eNOS immunostaining in balloon-injured carotid arteries 7, 14, and 28 days after injury and delivery of either (A), adenoviruses encoding
shScrambled (open bars) or shRNAs targeted to NRP1 (grey bars) and NRP2 (black bars), or (B), Ad.LacZ (open bars), Ad.NRP1 WT (grey bars),
and Ad.NRP1 DC (black bars), n ¼ 6 animals per treatment at each time point, *P, 0.05. (C–F) Effects of adenoviruses encoding shScrambled (black
line) or shRNAs targeted to NRP1 (grey line), NRP2 (dashed line) (C and E) or Ad.LacZ (black line), Ad.NRP1WT (grey line), and Ad.NRP1 DC (black
dashed line) (D and F ) on VEGF-induced RAoEC migration (C and D) or RAoEC proliferation (E and F ), each experiment counted 16 replicates and the
data represent the average of three independent experiments, *P, 0.05.
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vs. shScrambled, respectively) (Figure 4C) and proliferation (from 42
and 48 h onwards for shNRP1 and shNRP2 vs. shScrambled, respect-
ively) (Figure 4E).
The effect of NRP knockdown on endothelial function of carotid ar-
teries 14 days after angioplasty was assessed in organ bath studies of
vascular reactivity. These experiments demonstrated a significantly re-
duced contractile response in the injured arteries compared with the
uninjured arteries, but indicated no effect of Ad.shNRP1 or
Ad.shNRP2, compared with Ad.shScrambled (see Supplementary ma-
terial online, Figure S7A, Table S4). Relaxation of injured carotids was
also significantly less than that of uninjured arteries. We observed a
trend towards reduced relaxation in vessels treated with either
Ad.shNRP1 or Ad.shNRP2 compared with Ad.shScrambled, but the
differences were not statistically significant (see Supplementary mater-
ial online, Figure S7B, Table S5).
3.4 Neointimal cell proliferation
Two major mechanisms could explain the inhibitory effects of NRP in-
hibition on neointima formation: inhibition of neointimal cell migration
and/or reduced cell proliferation. Analysis of BrdU labelling in injured
carotid arteries 7 days after angioplasty, a time when neointimal cell
proliferation peaks in the rat carotid injury model,31 revealed abundant
BrdU-labelled neointimal cells with sparser labelled cells present in the
adventitia or media. Though this is likely to be duemainly to VSMC pro-
liferation, we do not preclude that some BrdU labelling could arise
from proliferation of inflammatory or endothelial cells. Although Ad.-
shRNAs targeting NRP1 and NRP2 both significantly reduced neointi-
mal thickening (Figure 3A), Ad.shNRP1 had no significant effect on
neointimal BrdU labelling, whereas Ad.shNRP2 caused a significant re-
duction in neointimal cell proliferation (see Supplementary material
online, Figure S8A). Furthermore, neither Ad.NRP1 WT nor Ad.NRP1
DC had any significant effect on VSMC proliferation within neointimal
lesions (see Supplementary material online, Figure S8B). In vivo prolifer-
ation was also assessed at 14 days post-injury, but very little prolifer-
ation was observed at this time (data not shown).
3.5 Role of neuropilins in migration and
proliferation of RAoSMC
Our results indicated that inhibition of NRP1 function in arterial VSMC
by either targeted knockdown or overexpression of NRP1 DC had lit-
tle effect on VSMC proliferation and, therefore, was likely to act pri-
marily by inhibiting directed cell migration. This possibility was
evaluated directly by examining the effect of shRNA-mediated knock-
down of NRP1 and NRP2 on the migratory response of primary cul-
tures of rat arterial SMC (RAoSMC) to PDGF-BB. Infection of
RAoSMCwith shRNAs targeted to rat NRP1 andNRP2 significantly re-
duced NRP protein expression in RAoSMC (Figure 6; see Supplemen-
tary material online, Figure S3C). NRP1 knockdown caused a significant
decrease in cell migration in response to PDGF-BB, as determined in
Transwell assays of chemotaxis and in scratch assays of wound closure
(chemokinesis), while NRP2 shRNA also significantly inhibited the mi-
gratory response to PDGF-BB, although to a lesser extent (Figure 5A
and C ). We next examined the effects of adenoviral overexpression
of NRP1 WT and the NRP1 DC mutant on PDGF-BB-induced
RAoSMC migration (Figure 5B). Infection of RAoSMC with Ad.NRP1
WT did not significantly alter the migration of RAoSMC towards a gra-
dient of PDGF-BB, compared with control cells infected with Ad.LacZ.
In contrast, Ad.NRP1 DC infection caused a significant inhibition of cell
migration induced by the PDGF-BB gradient (Figure 5B), indicating a
role for the NRP1 cytoplasmic domain in downstream signalling medi-
ating the chemotactic response of these cells, consistent with our pre-
vious findings in human VSMC.11 VSMC migration, as assessed by
scratch assay, was not affected by the overexpression of the Ad.NRP1
WT or DC constructs (data not shown).
Analysis of neointimal BrdU labelling in rat carotid arteries indicated
a role for NRP2 in VSMC proliferation. To test this directly, we com-
pared the effects of NRP1 and NRP2 shRNAs on the proliferation of
RAoSMC. Ad.shNRP1 had no effect on PDGF-BB-stimulated prolifer-
ation compared with Ad.shScrambled controls, whereas Ad.shNRP2
caused a small decrease in PDGF-BB-induced RAoSMC proliferation
(data not shown).
3.6 Regulation of PDGF signalling in rat
VSMC by neuropilins
The mechanisms mediating the role of NRPs in VSMC migration and
proliferation were addressed by investigating the effects of NRP knock-
down and adenoviral overexpression on PDGF receptor activation in
RAoSMC. As shown in Figure 6, PDGF treatment of RAoSMC induced
a marked increase in tyrosine phosphorylation of PDGFRb and
PDGFRa. NRP1- and NRP2-targeted knockdown using shRNA infec-
tion in these cells significantly decreased PDGFRa and PDGFRb tyro-
sine phosphorylation without affecting total PDGFR levels (Figure 6).
Adenoviral overexpression of NRP1 WT or NRP1 DC had no signifi-
cant effect on phosphorylation of either PDGFRb or PDGFRa in
RAoSMC (results not shown).
4. Discussion
NRPs are expressed in arterial VSMC and have been shown to mediate
PDGF signalling and migration in VSMC. NRP1 is also reported to be
most strongly expressed in late mouse embryos in the VSMC of large
vessels33 and in VSMC as well as endothelial cells in human coronary ar-
teries and aortae used for coronary artery bypass grafting.34 However,
hitherto, the role of NRPs in VSMC functions in vivo has not been inves-
tigated. A major conclusion of the present study is that NRP1 and NRP2
are both expressed in the VSMC of the carotid artery wall and are sig-
nificantly up-regulated at mRNA and protein levels in the carotid artery
after endothelial balloon injury. Both NRPs were most strongly ex-
pressed at 7 and 14 days post-injury, coincident with the most active
phase of neointimal VSMC accumulation and with the maximum extent
of neointimal thickening in this model. Further consistent with the notion
that NRPs are involved in neointimal VSMC accumulation, immunofluor-
escent staining revealed strong neointimal NRP1 and NRP2 expression
in the neointima further suggestive of expression in neointimal VSMC. It
was noted that whereas total arterial NRP1 and NRP2 protein expres-
sion declined at 28 days, NRP1 mRNA expression remained elevated at
this time, perhaps reflecting a later phase of NRP1 expression in the
endothelial repopulation of injured arteries.
The second important conclusion of this paper is that NRP1 and
NRP2 both contribute to neointimal VSMC hyperplasia and neointima
formation in the injured rat carotid injury model. This conclusion is
based on two major lines of evidence: (i) targeted shRNAs to either
NRP1 or NRP2, effective in reducing NRP expression in cultured rat
VSMC and in the carotid artery, significantly inhibited neointimal thick-
ening at 7, 14, and 28 days after endothelial balloon injury; (ii) adeno-
viral overexpression of an NRP1 DC mutant lacking the cytoplasmic
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domain, previously shown to inhibit VEGF- and PDGF-BB-induced mi-
gration of, respectively, endothelial cells and VSMC, also strongly inhib-
ited neointima formation at 7 and 14 days after injury. Given that NRP
inhibition using siRNA- or shRNA-mediated NRP1 and NRP2 knock-
down, or by overexpression of NRP1 DC, inhibits PDGF-BB-induced
migration of cultured primary human11 and rat arterial VSMC, we pro-
pose that the inhibitory effect of interfering with NRP function on
neointima formation results primarily from inhibition of VSMC migra-
tion, probably due to inhibition of PDGF-BB signalling, though whether
PDGF signalling is the only or major target for the action of NRP1 in-
hibition is not clear. For example, NRP1 also regulates signalling by
TGF-b and its receptors, which are important mediators of VSMC
proliferation.15,35,36 The inhibitory effect of Ad.NRP1DCon neointimal
hyperplasia is most likely due to a dominant negative effect of this con-
struct on NRP1 functions in VSMC dependent on its cytoplasmic do-
main, as we previously demonstrated in human VSMC.11 A role for
the NRP1 cytoplasmic domain in arteriogenesis has been demon-
strated in mice with a global knock-in of NRP1 lacking its cytoplasmic
region. These mice exhibit normal developmental angiogenesis, but im-
paired neonatal arteriogenesis in the heart, kidney, and hindlimb.37 The
NRP1 cytoplasmic domain is thought to function at least in part
through interaction of its C-terminal PDZ domain binding motif to
the PDZ domain protein, synectin, and this and other possible protein
interactions with the NRP1 cytoplasmic domain could play a scaffolding
Figure 5 Inhibition of NRP1 and NRP2 reduces PDGF-BB-induced Rat VSMC chemotaxis. RAoSMC were infected either with NRP1, NRP2, and
control Scrambled Ad.shRNAs (A) or with Adenoviruses encoding NRP1 WT, NRP1 DC, or LacZ (B), and after 24 h, infected cells were transferred
to Transwell filters, andmigrationwas determined in response to 30 ng/mL PDGF-BB (black bars), or no treatment (serum-freemedium, open bars). The
efficacy of NRP1 andNRP2 knockdown in RAoSMCwas assessed by western blot (see Supplementary material online, Figure S4C). Representative Trans-
well filters are shown for each treatment (bar scale represents 100 mm). Quantification of migration is presented as means+ SEM from three independ-
ent experiments, and each treatment was performed in triplicate; *P, 0.05, ** P, 0.01. (C) RAoSMC in 96-well plates were infected either with NRP1,
NRP2, and control Scrambled Ad.shRNAs for 48 h. Cells were then starved overnight before a precise scratch was generated using theWoundMakerTM
(Essen BioScience). Migration was assessed in the presence or absence of 10 ng/mL PDGF-BB, using an IncuCyte ZOOMw Live-Cell Imaging Platform.
The graph represents three independent experiments: means+ SEM; *P, 0.05 (from 10 h onwards) for Ad.Scrambled vs.Ad.shNRP1. * P, 0.05 (from
14 h onwards) for Ad.Scrambled vs. Ad.shNRP2. Each treatment per experiment was performed in 16 replicates.
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role in cell migration.5,37 The role of theNRP2 cytoplasmic domain is less
clear and warrants further investigation. A key role for NRP1 specifically
in neointimal VSMC migration is also inferred from the finding that nei-
ther NRP1 shRNA nor NRP1 DC caused inhibition of neointimal cell
proliferation measured by in vivo BrdU labelling. NRP1 knockdown also
had no effect on RAoSMC proliferation. Furthermore, previously pub-
lished work indicates an important role for NRP1 in directed cell migra-
tion induced by chemotactic cues such as PDGF-BB and VEGF, but that
NRP1 is unimportant for cell proliferation.4 –9,11,38 While we cannot
preclude NRP1 cytoplasmic domain playing a role in other cellular pro-
cesses contributing to neointimal hyperplasia, our present findings
strongly indicate that inhibition of NRP1 function in the rat carotid artery
selectively interferes with VSMC migration underlying neointimal VSMC
accumulation.
In contrast to NRP1, the cellular functions of NRP2 are less well
understood. Our finding that shRNA-mediated NRP2 knockdown in-
hibited neointima formation indicates a novel role for NRP2 in patho-
logical vascular remodelling. Since NRP2 knockdown also inhibited
PDGF-BB-induced chemotaxis of human11 and rat VSMC, our results
are consistent with NRP2 playing a role in directed VSMC migration
contributing to neointimal expansion. This may be mediated either in-
dependently of NRP1 by, for example, a direct interaction between
NRP2 and PDGFRa or b, and/or could arise from an interaction be-
tween NRP1 and NRP2. Our previous findings indicate that NRP1
and NRP2 readily associate with each other, consistent with the
conclusion that these molecules heterodimerize or form mixed
oligomers.9 The finding that the combination of shRNAs to NRP1
andNRP2 had no additive inhibitory effect on neointima formation sug-
gests that the two NRPs lie on the same pathway. Since Ad.shNRP2
also significantly reduced in vivo neointimal BrdU labelling and caused
a small decrease in RAoSMC proliferation, NRP2 may also contribute
to the proliferation as well as migration of VSMC, though further work
is required to support this conclusion.
The mechanism through which NRPs regulate PDGF-induced VSMC
chemotaxis has not been fully defined yet, but previous findings show
that NRP1 knockdown inhibits PDGF-induced PDGFRa activa-
tion.11,13,15 Herein we demonstrate that NRP1 and NRP2 knockdown
significantly reduced PDGFRa and PDGFRb tyrosine phosphorylation
in rat VSMC, consistent with our previous findings that NRP1 knock-
down inhibited PDGFR activation in human coronary artery VSMC.11
These results suggest that impaired PDGFR activation consequent
upon NRP knockdown contributes to the inhibitory effects of NRP
knockdown on VSMC migration in vivo after carotid injury and in cul-
tured VSMC. In contrast to the effects of NRP1 knockdown, overex-
pression of NRP1 DC had no significant effect on PDGFR activity,
consonant with our previous finding that this mutant had no effect
on activation of PDGFR or VEGFR in U87 glioma cells,6 and indicating
that the NRP1 cytosolic domain is not required for PDGFR activity in
rat VSMC. The differential roles of NRP1 and NRP2 in VSMC prolifer-
ation, and the underlying mechanisms involved, warrant further study.
In the rat balloon injury model, endothelial denudation triggers vas-
cular remodelling, resulting in rapid neointima formation due to the
Figure 6 NRP1 and NRP2 knockdown reduces PDGF-BB-induced phosphorylation of PDGFRa and PDGFRb in RAoSMC. RAoSMC were infected
with NRP1, NRP2, or control Scrambled (Scr) Ad.shRNAs, and after 48 h, infected cells were starved in serum-freemedium overnight before stimulation
for 10 min with 30 ng/mL PDGF-BB (+, black bars), or with serum-free medium only (2, open bars). Lysates were immunoblotted as indicated (A), and
data from three independent experiments were quantified (B, bars represent means+ SEM; *P, 0.05 vs. Ad.Scrambled + PDGF-BB).
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proliferation and migration of VSMC, which is followed by a slower re-
generation of the endothelium. In this latter process, based on genetic
and biochemical evidence pointing to a key role of endothelial NRP1 in
angiogenesis and directed endothelial cell migration,4 –9 NRP1 is hy-
pothesized to be essential for endothelial cell migration from contigu-
ous uninjured endothelium. This study is the first to examine the role of
NRPs in endothelial regeneration of a large artery and demonstrates
that targeted depletion of NRP1 or NRP2 using Ad.shRNAs markedly
reduced re-endothelialization at 7 and 14 days after balloon injury.
The retardation of re-endothelialization caused by NRP1 and NRP2
knockdowns is likely mediated by inhibition of endothelial cell migra-
tion and proliferation, a conclusion supported by the finding that
shRNAs targeted to NRP1 and NRP2 also reduced RAoEC migration
and proliferation. Conversely, overexpression of NRP1 WT signifi-
cantly enhanced endothelial re-coverage 14 and 28 days after endo-
thelial denudation and also augmented RAoEC migration. These data
are consistent with a large body of evidence supporting a role for
NRPs in mediating endothelial cell migration in vivo and in cells, and
support the conclusion that NRP1 and NRP2 play a significant role in
re-endothelialization.
Reduced re-endothelialization is predicted to enhance neointima
formation, whereas knockdown of NRPs strikingly decreased the I/M
ratio. This finding strongly argues that the inhibitory effect of NRP1
and NRP2 depletion on neointima formation is independent of the
role of NRPs in re-endothelialization and is instead mediated via a dir-
ect inhibitory effect on VSMC migration. Furthermore, the inhibitory
effects of Ad.NRP1 DC on neointimal hyperplasia at 7 days after injury
are unlikely to be due to its effects on re-endothelialization, since it had
no significant effect on re-endothelialization at this time.
In contrast, increased re-endothelialization is expected to
reduce neointimal hyperplasia, but Ad.NRP1 WT did not have such
an effect. We propose that this is because the enhancement of re-
endothelialization caused by Ad.NRP1WTmay not be sufficient to sig-
nificantly impact upon neointimal thickening. The trend towards en-
hancement of re-endothelialization by Ad.NRP1 DC was unexpected,
since previous studies showed that this construct inhibited migration of
HUVECs.6,11 However, though Ad.NRP1 DC significantly reduced
RAoEC migration, it had no significant effect on RAoEC proliferation.
These data suggest that endothelial cell proliferation and enhancement
of re-endothelialization by overexpression of NRP1 are largely depen-
dent on theNRP1 extracellular domain and do not require the intracel-
lular domain. In addition, re-endothelialization in vivo relies more on
endothelial proliferation, and consequently, inhibition of RAoECmigra-
tion by Ad.NRP1 DC may not impact so significantly upon re-
endothelialization. The significant reduction in neointimal thickening
caused by Ad.NRP1 DC is likely due to its direct inhibitory effects on
VSMC migration. Studies of endothelial contractility in injured carotid
arteries showed reduced responses following injury consistent
with previous findings,39 but showed no effect of NRP1 or NRP2
knockdown on the contractile response mediated via a1-adrenegric
receptor stimulation. We observed a tendency towards attenuated
endothelium-dependent relaxation in the carotid arteries treated
with Ad.shNRP1/2 compared with Ad.shScrambled, which, though not
significant, is consistent with our finding of reduced re-endothelialization
in response to NRP knockdowns.
These findings argue that a major role of NRP1 and NRP2 in early
arterial remodelling following endothelial damage is as a mediator of
VSMC migration contributing to neointimal expansion. NRPs are re-
quired for optimum endothelial regeneration, as indicated by the
inhibitory effects of NRP knockdown on re-endothelialization, but
this effect does not appear to be strong enough to counteract the in-
hibitory effect of targeted shRNAs on neointimal growth. This novel
role for NRP1 and NRP2 in mediating pathological arterial neointimal
hyperplasia in the rat injured carotid artery model suggests that these
receptors may be suitable targets for novel therapies designed to pre-
vent or reduce excessive VSMC accumulation in vascular proliferative
disorders. In particular, the ability of NRP1 DC to both reduce neoin-
timal hyperplasia, without impairing and even modestly enhancing re-
endothelialization, suggests that selective targeting of the NRP1
C-terminal domain could reduce neointimal hyperplasia while sparing
endothelial function.
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